|
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
|
BRUKINSA received the China NMPA approval for the treatment of patients with relapsed or refractory Waldenström’s macroglobulinemia (WM) in June 2021 The submission, supported by the ASPEN trial results, could potentially expand BRUKINSA to front-li...
Full "IntellAsia: Resources" article
|
|